Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 14/20 | 0.68 |
| ▸ | CA1 | P00915 | 10/20 | 0.68 |
| ▸ | CA12 | O43570 | 7/20 | 0.53 |
| ▸ | CA9 | Q16790 | 6/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.53 |
| ▸ | CA4 | P22748 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | NOS1 | P29475 | 1/20 | 0.47 |
| ▸ | CA5A | P35218 | 2/20 | 0.46 |
| ▸ | CA3 | P07451 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.46 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.46 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.45 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8519013 | 0.89 | ALDH1A1 (0.57) | CA2CA1ALDH1A1EPAS1 | |
| SCHEMBL2398133 | 0.82 | CA2 (1.00) | CA2CA1CA12CA9CA14 | |
| SCHEMBL686828 | 0.80 | LMNA (0.61) | CA2CA1CA12CA9CA14 | |
| SCHEMBL12860655 | 0.80 | ALDH1A1 (0.48) | CA2CA1ALDH1A1EPAS1NR1H3 | |
| SCHEMBL1156141 | 0.80 | ALDH1A1 (0.48) | CA2CA1ALDH1A1EPAS1NR1H3 | |
| SCHEMBL27851339 | 0.79 | ALDH1A1 (0.49) | CA2CA1ALDH1A1EPAS1 | |
| SCHEMBL6849852 | 0.79 | CA2 (0.57) | CA2CA1CA12CA9CA14 | |
| SCHEMBL17288903 | 0.78 | ALDH1A1 (0.50) | CA2CA1ALDH1A1EPAS1 | |
| SCHEMBL1272213 | 0.78 | ALDH1A1 (0.50) | CA2CA1CA12CA9ALDH1A1 | |
| SCHEMBL28224684 | 0.77 | ALDH1A1 (0.46) | CA2CA1ALDH1A1EPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4392397-A2 | PROCESS OF MAKING APOPTOSIS-INDUCING AGENTS | AbbVie Inc. (US) | 2024-07-03 | — | — | EP | claimed |
| WO-2023028558-A2 | PROCESS OF MAKING APOPTOSIS-INDUCING AGENTS | ABBVIE INC. (US) | 2023-03-02 | — | — | WO | claimed |
| WO-2026085795-A1 | SILENCED FC REGIONS | PROTEINTECH GROUP, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-4667469-A1 | COMPOUND CONTAINING TRIFLUOROMETHYLSULFONYL | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2025-12-24 | — | — | EP | disclosed |
| US-RE50643-E1 | Benzamide compounds | RECURIUM IP HOLDINGS, LLC (US) | 2025-10-21 | — | — | US | disclosed |
| WO-2025064952-A1 | BCL-2 INHIBITORS | Eil Therapeutics, Inc. (US) | 2025-03-27 | — | — | WO | disclosed |
| EP-4522154-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| CN-112703004-B | Methods and compositions for cancer treatment using recombinant dendritic cells | 雷诺瓦罗生物制药公司 | 2025-02-14 | — | — | CN | disclosed |
| CN-115697967-B | Sulfonylbenzamide derivative and conjugate thereof, preparation method and application thereof | 江苏恒瑞医药股份有限公司 | 2024-10-22 | — | — | CN | disclosed |
| WO-2024169976-A1 | COMPOUND CONTAINING TRIFLUOROMETHYLSULFONYL | 正大天晴药业集团股份有限公司 | 2024-08-22 | — | — | WO | disclosed |
| CN-114177308-B | Anti-cMet antibody drug conjugates and methods of use thereof | 艾伯维生物制药股份有限公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-114246953-A | anti-cMet antibody drug conjugates and methods of use thereof | 艾伯维生物制药股份有限公司 | 2022-03-29 | — | — | CN | disclosed |
| CN-114177308-A | anti-cMet antibody drug conjugates and methods of use thereof | 艾伯维生物制药股份有限公司 | 2022-03-15 | — | — | CN | disclosed |
| CN-114126616-A | Nanoparticle formulations of BCL-2 inhibitors | 里科瑞尔姆IP控股有限责任公司 | 2022-03-01 | — | — | CN | disclosed |
| CN-106008322-A | BCL-2-selectively apoptosis-inducing agents for the treatment of cancer and immune diseases | ABBVIE 公司 | 2016-10-12 | — | — | CN | disclosed |
| CN-106008466-A | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | 艾伯维公司 | 2016-10-12 | — | — | CN | disclosed |
| US-8809352-B2 | Sulfonamides as inhibitors of Bcl-2 family proteins for the treatments of cancer | NOVARTIS AG (CH) | 2014-08-19 | — | — | US | disclosed |
| US-20120165298-A1 | SULFONAMIDE COMPOUNDS | NOVARTIS AG (CH) | 2012-06-28 | — | — | US | disclosed |
| CN-102307622-A | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBOTT LAB | 2012-01-04 | — | — | CN | disclosed |
| CN-102307872-A | BCL-2-selectively apoptosis-inducing agents for the treatment of cancer and immune diseases | ABBOTT LAB | 2012-01-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165298-A1 | SULFONAMIDE COMPOUNDS | BCLAF1, BCL2L11, BCL2 | CA2 604/4885CA1 3106/4885CA12 1733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.